Quia Pharma clarifies intention ahead of delisting
The company intends to raise new capital for a composition with creditors, resume collaboration with QUIA NZI and delist from Nasdaq First North.
See the latest news and media coverage for Quia Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: Quia Pharma faced delisting from Nasdaq First North amid financial distress, leadership turnover, and multiple service contract terminations.
The company intends to raise new capital for a composition with creditors, resume collaboration with QUIA NZI and delist from Nasdaq First North.
The agreement is terminated due to unpaid invoices with effect from 18 November 2025.
Nasdaq decides on delisting due to missed payments and lack of business activity. The company agrees and cooperates for an orderly process. Focus is on GLP-1 patch as a private company.
BDO Mälardalen requests withdrawal due to unpaid fee for 2024. The company engages a new auditor immediately.
The chart above depicts the distribution of Revenue for companies operating in the Healthcare Sector in the Developed economic region. Over 1,740 companies were considered...
ZURICH and ZUG, Switzerland and STOCKHOLM, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Veld...
Find the latest Quia Pharma AB (publ) (QUIA.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements...
Track Quia Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.